What's going on with the Polynovo share price today?

The strong start has dissipated for Polynovo shares.

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares edge 1.54% higher to $1.32 after reaching an intraday high of $1.41 in morning trade 
  • Polynovo chair David Williams again took advantage of the recent share price weakness, buying $231,000 worth of Polynovo shares 
  • The company's share price touched a 52-week low of 83.5 cents earlier this month 

The Polynovo Ltd (ASX: PNV) share price rocketed as high as 8.65% during market open but has since fallen wayside.

At the time of writing, the medical device company's shares are swapping hands at $1.32, up 1.54%.

This follows the All Ordinaries Index's (ASX: XAO) lead which rose to an intraday high within the first hour of trade.

However, since then, the broader ASX index has given back its gains to fetch at 7, 328 points, up 0.28%.

Director tops up on Polynovo shares

An insider has again recently taken advantage of the Polynovo share price weakness to top up their holdings.

In its most recent statement, Polynovo revealed that its chair, David Williams picked up more shares.

In total, 181,532 Polynovo shares were bought through his subsidiary, Lawn Views Pty Ltd via an on-market trade.

The indirect acquisition occurred on 13 May, and the average price paid per Polynovo share was $1.2746.

This means that Mr Williams now has around 21.50 million fully paid ordinary Polynovo shares across all his holdings.

The above transaction equated to the value of more than $231,000.

It is worth nothing that in the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents. Since then, a number of directors, particularly Mr Williams have made a series of purchases.

Polynovo share price snapshot

It appears that the latest purchases could be spooking short sellers to close on their positions. ASIC is due to release its short position report mid-week, which will indicate where Polynovo shares are at.

On 9 May, the company had a reported short interest of 10.54%. This puts Polynovo as one of the most shorted shares on the ASX.

Despite this month's gains, Polynovo shares have fallen by around 50% over the past 12 months.

Based on today's price, Polynovo commands a market capitalisation of roughly $860.19 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »